CBSA and BIO urge you to reach out to Senator Hickenlooper to encourage his support of S.4583, a bill that would reauthorize the rare pediatric disease priority review voucher (PPRV) program before it expires on September 30, 2024. As NORD explains, the PPRV “has helped spur rare disease drug development in pediatric populations and brought almost four dozen therapies to market with critical safety and dosing data specific to children.” In a recent opinion piece in STAT News, rare disease parents Joe and Courtney Dion stress that the PPRV program is “one of the great victories” among “important reforms aimed at encouraging more research into rare diseases.”
CBSA and BIO thank the sponsors of the House bill to reauthorize the PPRV for six years advanced by the House Energy & Commerce Committee’s Health Subcommittee…
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
